AP706A - Injectable quinolone formulations. - Google Patents
Injectable quinolone formulations. Download PDFInfo
- Publication number
- AP706A AP706A APAP/P/1996/000898A AP9600898A AP706A AP 706 A AP706 A AP 706A AP 9600898 A AP9600898 A AP 9600898A AP 706 A AP706 A AP 706A
- Authority
- AP
- ARIPO
- Prior art keywords
- solution
- formulation
- danofloxacin
- added
- pvp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Aqueous pharmaceutical solutions suitable for "injection into a host, having improved injection site toleration, comprise danofloxacin or its pharmaceutically acceptable salts and a magnesium or zinc compound. The zinc compound in addition requires the presence of a co-solvent.
Description
INJECTABLE QUINOLONE FORMULATIONS
This invention relates to aqueous pharmaceutical solutions which are suitable for injection into animals and comprise the antibacterial agent danofloxacin with a magnesium or zinc compound.
It is generally known that quinolone carboxylic acids on injection into a host have a tendency to cause tissue damage at the injection site. One way of alleviating this problem is disclosed in U.S. Patent No. 5,235,054 describing introduction of a 3carboxyaldehyde prodrug group to replace the 3-carboxy group in certain quinolone carboxylic acids.
U.S. Patent Nos. 4,018,889 and 4,126,680 disclose injectable, high dosage, aqueous solutions of tetracycline antibiotics in the co-solvents 2-pyrroiidone, and caprolactam or 2-piperidone, respectively. The patents also mention addition of magnesium ions to the aqueous solutions to increase the physical stability, minimizing precipitation of the solutions by formation of magnesium-tetracycline chelates.
The present invention improves injection site toleration of injectable aqueous danofloxacin solutions by incorporation of certain metal compounds. It is believed that the metal compounds form complexes with danofloxacin so increasing the solubility thereof in water. It is further believed that the increased water solubility results in the improved toleration at the injection site.
This invention relates to an aqueous pharmaceutical solution which is suitable for injection into a host comprising danofloxacin or a pharmaceutically acceptable salt thereof in an amount sufficient for the treatment of bacterial infections, and (1) a magnesium compound, or (2) a mixture of a zinc compound with a co-solvent; said compounds and said co-solvent being present in amounts which are sufficient for improved toleration at the injection site.
In a preferred embodiment of the invention, the magnesium compound is present together with a co-solvent. In a further preferred embodiment the co-solvent of the magnesium compound or the zinc compound is at least one of 2-pyrrolidone, propylene glycol, polyethylene glycol, and N-methyl pyrrolidone, each optionally together with polyvinylpyrrolidone.
The aqueous pharmaceutical solution preferably contains an antioxidant, such as sodium formaldehyde sulfoxylate for increased stability. The solution is usually adjusted to a pH of about 5 to about 9.5, preferably from about 6.5 to about 9.0.
AP/P/ 96/00898
AP.00706
-2The invention also comprises a method for the treatment of bacterial infections in a host by injecting into said host an aqueous pharmaceutical solution comprising danofloxacin or a pharmaceutically acceptable salt thereof in an amount sufficient for the treatment of bacterial infections, and a (1) magnesium compound, or a (2) zinc compound in admixture with a co-soivent; said compounds and said co-solvent being present in amounts which are sufficient for improved toleration at the injection site.
Danofloxacin is 1-cyclopropyl-6-fluoro-7-{(1S,4S)-5-methyl-2,5diazabicyclo[2.2.1]hept-2-yl}-4-oxo-3-quinoline carboxylic acid, disclosed in U.S. Patent No. 4,861,779..
Suitable magnesium compounds of use in the invention include magnesium oxide and magnesium chloride. The magnesium compound is present in amounts that are sufficient to increase injection site toleration. The molar ratio of magnesium to danofloxacin or a pharmaceutically acceptable salt thereof (hereafter the active compound) usually ranges from about 0.25 to about 2, preferably about 0.8 to 1.2, such as about 1.
The zinc compound of use in the invention includes zinc oxide and zinc acetate. The molar ratio of zinc to the active compound ranges from about 0.3 to about 0.7, preferably about 0.5.
A co-solvent is understood to be a pharmaceutically acceptable liquid that can 20 be added to an injectable formulation. It has been found that the zinc compound must be administered with a co-solvent to be effective in improving the injection site toleration. The amount of co-solvent together with the amount of zinc compound is such that improved injection site toleration is obtained. Small amounts of a few, e.g., 1 to 3, weight percent of co-solvent based on the zinc compound may improve injection site toleration. However, usually higher amounts of about 30 to 50% by weight of cosolvent will be used to obtain optimum injection site toleration.
It was found that a co-solvent when used in combination with a magnesium compound increased the physical stability of the injectable solution containing the magnesium compound. The amounts of co-solvent to be used are from 0 to 50% by weight, usually from about 15 to 45% by weight, based on the magnesium compound.
Examples of co-solvents are at least one of 2-pyrrididone, propylene glycol, polyethylene glycol and N-methylpyrrolidone. The polyethylene glycol may have a molecular weight of from about 200 to about 400, preferably about 300.
AP/P/ 96/00898
AP . Ο Ο 7 Ο 6
-3Poiyvinylpyrrolidone (PVP) having a molecular weight of between about 5,000 and 100,000 (K-12 to K-30) may be present in a concentration of from about 1 to 10%, e.g., about 5%, by weight to increase tissue toleration.
The stability of the present aqueous compositions is enhanced by the use of 5 antioxidants at levels of from about 0.01 to about 1.0% by weight. Examples of suitable antioxidants are at least one of sodium metabisulfite, sodium sulfite, sodium formaldehyde suifoxylate, sodium formaldehyde sulfoxylate with ethylenediamine tetraacetic acid (EDTA), sodium thiosulfate, acetylcysteine, thioglycerol, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), σ-tocopherol, monoethanolamine, triethanolamine, citric acid, tartaric acid, EDTA, EDTA with citric acid, EDTA with BHA, EDTA with sodium metabisulfite, and triethanolamine with BHA.
The pH of the aqueous compositions of the invention generally ranges from about 5 to about 9.5, suitably from 6.5 to 9.0, most preferably 7.5, to obtain physically stable solutions. Suitable components to adjust the pH include bases and acids, such as sodium hydroxide or monoethanolamine, and hydrogen chloride or lactic acid, respectively.
The pharmaceutically acceptable acid addition salts of danofloxacin include salts with pharmaceutically acceptable acids such as acetic, lactic, succininic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, methanesulfonic, cinnamic, furmaric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfam, pivalic, stearic and sulfonic acid. These salts are prepared in a conventional manner by treating a solution or suspension of the quinolone compound with about one chemical equivalent of a pharmaceutically acceptable acid.
The solutions of the invention are readily prepared by mixing the co-solvent, when present, with the PVP, when present, and water, until the PVP is dissolved. The solution is conveniently heated, e.g., to 50°C, and the magnesium or zinc compound added. After addition of the active compound and continued stirring, a solution is usually formed. The composition may be held at a slightly elevated temperature during stirring. If necessary, either before or after addition of the active compound, the pH is adjusted by addition of a base or acid, and the remainder of the water is added to form a solution. In general, the solutions are prepared such that exposure to oxygen is reduced to minimize chemical degradation of the ingredients in the solutions.
AP/P/ 96/00898
AP.00706 aIt has been found that bioavailability and antibacterial activity in vivo of the present pharmaceutical compositions are comparable to those of the prior art.
The pharmaceutical solutions of the invention are conveniently injected into the host such as cattle by subcutaneous injection.
The dosage of the active compound may vary according to administration methods, age and weight of the host, severity of the infection and the like, and usually ranges from about 1 to 10 mg/kg/day. The aqueous solutions of the invention contain the active compound in an amount ranging from about 25 to 300 mg/mL, preferably from about 60 to about 200, such as 180 mg/ml_
The following standard procedure was used to evaluate the injection site toleration of the pharmaceutical solutions of the invention. Calves weighing 200-300 kg were injected subcutaneously with a pharmaceutical solution according to the invention either on a milligram per kilogram or on a volume dependent basis. Each formulation was administered at a minimum of three sites. Subcutaneous injections were made in the neck region. The calves were observed immediately post-injection for signs of intolerance (i.e.. pain). Injection sites were observed grossly and palpated to detect swelling at 24 hours post-injection and once weekly for the duration of the 28 day study. At 28 days post-injection, the calves were euthanized. The injection sites were removed and chilled overnight to facilitate examination. Subcutaneous sites were removed with the hide and underlying muscle intact. The injection sites were examined for gross lesions and the character and extent of the gross lesions were evaluated according to standard guidelines.
The subcutaneous injection sites were rated acceptable if there was no necrosis or a small amount of necrosis which could easily be trimmed from the site. They were rated unacceptable if there was marked fascia and/or muscle necrosis.
The following Examples illustrate the invention and do not limit the scope of the invention to the specific details therein. In general, during manufacture of the formulations in the Examples, exposure of the formulations to oxygen was reduced, e.g. by bubbling nitrogen through them and/or by maintaining a nitrogen head space in the vessel used. The formulations were packaged in vials whose head space was flushed with nitrogen.
AP/P/ 9 6 / 0 0 8 9 8
AP.00706
-5EXAMPLE 1
The following formulation was prepared:
a/100 mL | |
danofloxacin | 6.00 |
2-pyrrolidone | 40.02 |
polyvinylpyrrolidone (PVP) | 5.01 |
MgO | 0.68 |
sodium formaldehyde sulfoxylate (SFS) | 0.20 |
HCI | qs to pH 7.8 |
water | qs to 100 mL |
The 2-pyrrolidone, the PVP, and the water estimated necessary to produce 200 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The sodium formaldehyde sulfoxylate was added and dissolved. The magnesium oxide was added. The resulting slurry was subdivided into two portions. The danofloxacin was added to a portion of the slurry weighing 94.04 g. The formulation was held at about 50°C and agitated for approximately one hour. It had a cloudy gold appearance and contained some suspended matter. The formulation was cooled to room temperature and the pH adjusted to 7.8 with the HCI to form a solution. Following agitation for 2 hours, the pH of the solution was 8.0.
The solution contained 60 mg/mL of danofloxacin based on a potency of 1000 mg/g for the lot of danofloxacin used.
EXAMPLE 2
6 8 0 0 / 9 6 Zd/dV
a/500 mL | |
danofloxacin mesylate | 40.1 |
2-pyrrolidone | 198.2 |
polyvinylpyrrolidone (PVP) | 24.8 |
ΑΡ.ΟβΤβδ
a/500 mL | |
MgO | 3.3 |
sodium formaldehyde sulfoxylate (SFS) | 1.0 |
HCI | 1.6 |
water | qs to 500 mL |
The 2-pyrrolidone, the PVP, and most of the water estimated necessary to produce 2000 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The sodium formaldehyde sulfoxylate was added and dissolved and then the magnesium oxide was added. The resulting slurry was cooled to room temperature and held for future use. The slurry was resuspended and 500 g was subdivided. The 500 g portion was heated to about 50°C, and the danofioxacin mesylate was added. After the formulation was held at about 50°C and agitated for approximately one hour, it was yellow and contained a small amount of suspended material. After cooling to room temperature, the pH was adjusted to 8.3 with the HCI, and the formulation was agitated for approximately 22 hours. Following agitation, this formulation was a solution. A sufficient quantity of water was added to produce the desired volume of 500 mL The pH of the resulting formulation was 8.3 and contained 60 mg/mL of danofioxacin based on a potency of 748 mg/g for the lot of danofioxacin mesylate used.
EXAMPLE 3
AP/P/ 96/00898
g/600 mL | |
danofioxacin mesylate | 48.5 |
2-pyrrolidone | 240.0 |
polyvinylpyrrolidone (PVP) | 30.1 |
MgO | 4.0 |
HCI | 2.1 |
a/600 mL | |
water | qs to 600 mL |
The 2-pyrrolidone, the PVP, and most of the water were combined and agitated until the PVP dissolved. The solution was heated to about 50°C, and the magnesium oxide was added. The danofloxacin mesylate was added to the resulting slurry. The formulation was held at about 50°C and agitated for approximately one hour forming a gold hazy suspension with numerous fine particles. The suspension was cooled to room temperature and held overnight. After the pH was adjusted to 8.2 with the HCI, the formulation was agitated for approximately 20 hours to form a solution. A sufficient quantity of water was added to produce the desired volume of 600 mL. The pH of the formulation was 8.4.
The solution contained 60 mg/mL of danofloxacin based on a potency of 742 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 4
a/50 mL | |
danofloxacin mesylate | 16.11 |
2-pyrrolidone | 16.99 |
polyvinylpyrrolidone (PVP) | 2.51 |
MgO | 1.35 |
sodium formaldehyde sulfoxylate (SFS) | 0.10 |
HCI | 1.49 |
water | qs to 50 mL |
6 8 0 0 / 9 6 /d/dV
The 2-pyrrolidone, the PVP, and most of the water necessary to produce 100 25 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The magnesium oxide was added, then the sodium formaldehyde sulfoxylate and the danofloxacin mesylate. The resulting slurry
AP . ο 0 7 ο 6
-8was held at about 50°C and agitated for approximately one hour resulting in a light brown formulation containing considerable suspended material. The formulation was subdivided and one half was cooled to room temperature. The pH was adjusted to 8.2 with the HCI and the formulation agitated overnight to form a dear, yellow solution. The volume of the solution was approximately 50 mL and the pH was 8.2.
The solution contained 240 mg/mL of danofloxacin based on a potency of 745 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 5
a/50 mL | |
danofloxacin mesylate | 20.14 |
2-pyrrolidone | 14.53 |
polyvinylpyrrolidone (PVP) | 2.51 |
MgO | 1.68 |
sodium formaldehyde sulfoxylate (SFS) | 0.10 |
HCI | 0.76 |
water | qs to 50 mL |
AP/P/ 96/00898
The 2-pyrrolidone, the PVP, and most of the water necessary to produce 100 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The magnesium oxide was added, then the sodium formaldehyde sulfoxylate and the danofloxacin mesylate. The resulting slurry was held at about 50°C and agitated for approximately one hour to form a light brown formulation containing considerable suspended material. The formulation was subdivided: one half was cooled to room temperature, and the pH was adjusted to 8.3 with the HCI. The solution was agitated overnight to form a yellow, opalescent suspension. A sufficient quantity of water was added to produce the desired volume of 50 mL. The pH of the formulation was 8.3.
The formulation was centrifuged and the supernatant filtered through a 0.22 micron filter. The filtrate solution contained 298 mg/mL of danofloxacin.
-9EXAMPLE 6
a/1000 mL | |
danofloxacin mesylate | 242.0 |
2-pyrrolidone | 400.0 |
polyvinylpyrrolidone (PVP) | 50.1 |
MgO | 20.2 |
HCI | 18.0 |
water | qs to 1000 mL |
The 2-pyrrolidone, the PVP, and a portion of the water were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The magnesium oxide was added. The danofloxacin mesylate was added to the resulting slurry. The formulation was held at about 50°C and agitated for approximately one hour to form a dark brown formulation containing a small amount of suspended material. The formulation was cooled to room temperature and the pH was adjusted to 8.2 with the HCI. Following overnight agitation, a dark brown solution was formed. A sufficient quantity of water was added to produce the desired volume of 1000 mL The pH of the solution was 8.4 and the solution contained 180 mg/mL of danofloxacin based on a potency of 745 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 7
AP/P/ 9 6 / 0 0 8 9 8
q/300 mL | |
danofloxacin mesylate | 72.4 |
2-pyrrolidone | 120.0 |
polyvinylpyrrolidone (PVP) | 15.0 |
MgO | 6.1 |
sodium formaldehyde sulfoxylate (SFS) | 0.6 |
AP.00706
g/300 mL | |
HCI | 2.4 |
water | qs to 300 mL |
The 2-pyrrolidone, the PVP, and a portion of the water were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The magnesium oxide was added. After the danofloxacin mesylate was added to the resulting slurry, the formulation was held at about 50°C and agitated for approximately one hour. The sodium formaldehyde sulfoxylate was added, and the solution held at about 50°C and agitated for less than 20 minutes. After the formulation was cooled to room temperature, the pH was adjusted to 8.1 with the HCI. After agitation overnight, the formulation was gold and contained a small amount of suspended material. A sufficient quantity of water was added to produce the desired volume of 300 mL and a pH of 8.4. The formulation was passed through a paper filter to remove a small amount of suspended material.
The solution formed contained 180 mg/mL of danofloxacin based on a potency of 745 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 8
a/300 mL | |
danofloxacin mesylate | 72.5 |
polyvinylpyrrolidone (PVP) | 15.0 |
MgO | 3.0 |
NaOH | 1.6 |
water | qs to 300 mL |
AP/P/ 96/00898
The PVP and a portion of the water were combined and agitated until the PVP dissolved. The formed solution was heated to about 50° C. The magnesium oxide was added, and the danofloxacin mesylate was added to the resulting slurry. The
AP . ο Ο 7 Ο 6
-11formulation was held at about 50°C and agitated for approximately one hour to form a dark brown solution. After the formulation was cooled to room temperature, the pH was adjusted to 8.0 with the NaOH. Following agitation overnight, the formulation was a dark brown solution. A sufficient quantity of water was added to produce the desired volume of 300 mL at a pH of 8.0.
The solution contained 180 mg/mL of danofloxacin based on a potency of 745 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 9
- | a/300 mL |
danofloxacin mesylate | 72.8 |
polyvinylpyrrolidone (PVP) | 15.0 |
MgO | 6.0 |
lactic acid | 6.8 |
water | qs to 300 mL |
The PVP and a portion of the water were combined and agitated until the PVP dissolved. The magnesium oxide was added, and the danofloxacin mesylate was added to the resulting slurry. After the formulation was agitated for a period of time, the pH was adjusted to 8.1 with the lactic acid. A sufficient quantity of water was added to produce the desired volume of 300 mL. Following agitation overnight, the formulation was a clear, light brown solution and the pH was 8.1.
The solution contained 180 mg/mL of danofloxacin based on a potency of 742 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 10
AP/P/ 96/00898
a/300 mL | |
danofloxacin mesylate | 71.9 |
2-pyrrolidone | 118.5 |
polyvinylpyrrolidone (PVP) | 14.9 |
AP . ο ο 7 ο 6
a/300 mL | |
ZnO | 6.0 |
NaOH | 3.7 |
water | qs to 300 mL |
The 2-pyrrolidone, the PVP, and a portion of the water necessary to produce 400 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C. The zinc oxide was added, and the danofloxacin mesylate was added to the resulting slurry. The formulation was held at about 50°C, agitated for approximately one hour, subdivided, and cooled to room temperature. The pH was adjusted to 8.0 with the NaOH. A sufficient quantity of water was added to produce the desired volume of 300 mL at a pH of 8.0. The formulation was passed through a paper filter to remove a small amount of suspended material so resulting in a clear brown solution.
The solution contained 178 mg/mL of danofloxacin based on a potency of 742 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 11
a/300 mL | |
danofloxacin mesylate | 72.8 |
2-pyrrolidone | 120.1 |
zinc acetate | 13.7 |
NaOH | 7.3 |
water | qs to 300 mL |
AP/P/ 96/00898
The 2-pyrrolidone and a portion of the water were combined and the solution 25 was heated to about 50°C. After addition of the zinc acetate and the danofloxacin, the formulation was heated to about 50°C, and held at that temperature and agitated for approximately one hour. The resulting formulation, which was dark brown with a small
AP . Ο Ο 7 Ο 6
-13amount of suspended material, was cooled to room temperature with increased formation of suspended material. The pH was adjusted to 7.7 with the NaOH. A sufficient quantity of water was added to produce the desired volume of 300 mL. Following agitation overnight, the formulation was a solution with a pH of 7.7.
The solution contained 180 mg/mL of danofioxacin based on a potency of 742 mg/g for the lot of danofioxacin mesylate used.
EXAMPLE 12
a/564 mL | |
danofioxacin mesylate | 133.8 |
2-pyrrolidone | 225.7 |
polyvinylpyrrolidone (PVP) | 28.3 |
MgO | 11.4 |
sodium formaldehyde sulfoxylate (SFS) | 1.1 |
HCI | 27.5 |
water | qs to 554 mL |
The 2-pyrrolidone, the PVP, and a portion of the water necessary to produce 1000 mL of the formulation were combined and agitated until the PVP dissolved. After the solution was heated to about 50°C, the magnesium oxide was added. After the danofioxacin mesylate was added to the resulting slurry, the formulation was held at about 50°C and agitated for approximately one hour to form a suspension. After cooling to room temperature, the pH of the formulation was adjusted to 5.9 with the HCI. Following.agitation for approximately one hour, the formulation was a clear brown solution. A sufficient quantity of water was added to produce a volume of 1000 mL at a pH of 5.8. Approximately 563 mL of the formulation was heated to about 50°C, and the sodium formaldehyde sulfoxylate was added and dissolved with agitation. The formulation was held at about 50°C, agitated for approximately one hour and cooled to room temperature. The formulation was a clear yellow solution with a pH of 5.8.
AP/P/ 9 6 / 0 0 8 9 8
AP . Ο Ο 7 Ο 6
-14The solution contained 180 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 13
g/694 mL | |
danofloxacin mesylate | 164.3 |
2-pyrrolidone | 277.1 |
polyvinylpyrrolidone (PVP) | 34.7 |
MgO | 14.0 |
sodium formaldehyde sulfoxyiate (SFS) | 1.4 |
HCI | 0.7 |
NaOH | 0.3 |
water | qs to 694 mL |
The 2-pyrrolidone, the PVP, and a portion of the water necessary to produce
1000 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C, the magnesium oxide was added, and the danofloxacin mesylate was added to the resulting slurry. The formulation was held at about 50°C, agitated for approximately one hour to form a suspension and cooled to room temperature. The pH was 8.5. Following agitation overnight, the pH was 8.8 and a few suspended particles remained. A sufficient quantity of water was added to produce a volume of 1000 mL and a pH of 8.2. Approximately 693 mL of the formulation was heated'to about 50° C, the sodium formaldehyde sulfoxyiate was added, and dissolved with agitation. The formulation was held at about 50°C for approximately one hour and cooled to room temperature resulting in a clear yellow solution with a pH of 8.8.
The solution contained 180 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
6 8 0 0 / 9 6 /d/d\J
AP.00706
-15EXAMPLE 14
a/704 mL | |
danofloxacin mesylate | 166.9 |
2-pyrrolidone | 176.2 |
polyvinylpyrrolidone (PVP) | 52.9 |
MgO | 14.2 |
sodium formaldehyde sutfoxyiate (SFS) | 1.4 |
HCI | 17.0 |
water | qs to 704 mL |
The 2-pyrrolidone, the PVP, and a portion of the water necessary to produce 1000 mL of the formulation were combined and agitated until the PVP dissolved. The solution was heated to about 50°C, and the magnesium oxide was added. The danofloxacin mesylate was added to the resulting slurry. The formulation was held at about 50°C and agitated for approximately one hour forming a suspension. After cooling to room temperature, the pH of the formulation was adjusted to 8.0 with a portion of the HCI. Following agitation overnight, the pH was 8.5, which was adjusted to 8.0 with additional HCI. The formulation was agitated for approximately two hours to form a clear brown solution. A sufficient quantity of water was added to produce a volume of 1000 mL and a pH of 8.2. Approximately 703 mL of the formulation was heated to about 50°C, the sodium formaldehyde sutfoxyiate was added and dissolved with agitation. The formulation was held at about 50°C, agitated for approximately one hour and cooled to room temperature forming a clear yellow solution which contained 180 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
6 8 0 0 / 9 6 /d/dV
AP.00706
-16EXAMPLE 15
a/1000 mL | |
danofioxacin mesylate | 237.6 |
2-pyrrolidone | 400.0 |
polyvinylpyrrolidone (PVP) | 50.1 |
zinc acetate | 40.8 |
sodium formaldehyde sulfoxylate (SFS) | 2.0 |
NaOH | 28.3 |
water | qs to 1000 mL |
The 2-pyrrolidone, the PVP, and a portion of the water were combined and agitated until the PVP dissolved. The SFS was added to the solution and dissolved with agitation. The solution was heated to about 50°C. A portion of the zinc acetate and the danofioxacin mesylate were added. The formulation was held at about 50°C, agitated for approximately one hour and cooled to room temperature. The sodium hydroxide was added to the suspension in several portions. After the final addition, the pH was 8.0. The balance of the zinc was added and the formulation was heated to about 50°C, held at that temperature, agitated for approximately one hour and then cooled to room temperature. A sufficient quantity of water was added to produce 1000 mL of a clear yellow solution with a pH of 8.0. The solution contained 180 mg/mL of danofioxacin based on a potency of 759 mg/g for the lot of danofioxacin mesylate used.
AP/P/ 96/00898
ΑΡ δύ706 e *»
-17EXAMPLE 16
a/250 mL | |
danofloxacin mesylate | 59.3 |
2-pyrrolidone | 100.2 |
polyvinylpyrrolidone (PVP) | 12.5 |
magnesium chloride | 11.9 |
sodium formaldehyde sulfoxylate (SFS) | 0.5 |
NaOH | 6.5 |
water | qs to 250 mL |
The 2-pyrrolidone, the PVP, and a portion of the water were combined and
I agitated until the PVP dissolved. The SFS was added to the solution and dissolved with agitation. The magnesium chloride and the danofloxacin mesylate were added. The pH was adjusted to 8.1 with the NaOH. Following agitation overnight, a sufficient quantity of water was added to produce 250 mL of a dark yellow solution with a pH of 7.8.
OO σ>
oo <o o
co cr>
«X
The solution contained 180 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 17
a/1000 mL | |
danofloxacin mesylate | 237.3 |
propylene glycol | 250.0 |
polyvinylpyrrolidone (PVP) | 50.1 |
MgO | 20.1 |
sodium formaldehyde sulfoxylate (SFS)' | 3.1 |
AP. 0 70 6
a/1000 mL | |
HCI | 17.7 |
water | qs to 1000 mL |
The propylene glycol, the PVP, and a portion of the water were combined and 5 agitated until the PVP dissolved. After the solution was heated to about 50°C, the magnesium oxide was added. The danofloxacin mesylate was added to the resulting slurry. Agitating for approximately one hour at about 50°C, the formulation was brown with suspended material. The formulation was cooled to room temperature, and the pH was adjusted to 7.9 with the HCI. The formulation was agitated overnight. After additional agitation, it was amber and contained some suspended material. A sufficient quantity of water was added to produce a 1000 mL solution with a pH of 8.0.
The solution contained 180 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 18
a/1500 mL | |
danofloxacin mesylate | 237.2 |
polyethylene glycol 300 (PEG) | 251.5 |
polyvinylpyrrolidone (PVP) | 50.1 |
MgO | 20.2 |
sodium formaldehyde sulfoxylate (SFS) | 3.1 |
HCI | 51.9 |
water | qs to 1500 mL |
6 8 0 0 / 9 6 /d/dV
The PEG, the PVP, and a portion of the water necessary to produce 1000 mL 25 of a formulation containing 25% PEG and 5% PVP were combined and agitated until the PVP dissolved. The solution was heated to about 50°C, and the magnesium oxide
AP.00706
-19was added. The danofloxacin mesylate was added to the resulting slurry, which was then agitated for approximately one hour at about 50°C. The formulation was light brown and contained a considerable amount of suspended material. After cooling to room temperature, it became a semi-solid with a pH of 7.9. Approximately 500 mL of water was added, the pH was adjusted to 6.2 with HCl, and the formulation was agitated overnight. After additional agitation, a clear amber solution was formed with a pH of 5.5 and containing a few large suspended particles. After the pH was adjusted to 6.1 with the NaOH, the formulation was amber and contained some suspended material. A sufficient quantity of water was added to produce a 1500 mL solution at a pH of 6.2.
The solution contained 120 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 19
a/4000 mL | |
danofloxacin mesylate | 949 |
2-pyrrolidone | 800 |
polyvinylpyrrolidone (PVP) | 200 |
MgO | 81 |
HCl | 174 |
liquefied phenol | 11 |
sodium formaldehyde sulfoxylate (SFS) | 10 |
water | qs to 4000 mL |
AP/P/ 96/00898
The 2-pyrrolidone, the PVP, and a portion of the water necessary to produce 25 4000 mL of the formulation were combined and agitated until the PVP dissolved. Most of the HCl was added to the solution, then the magnesium oxide was added. The danofloxacin mesylate was added to the resulting slurry to form a dark brown solution with suspended material. After the formulation was agitated overnight and the pH adjusted to 7.5 with the remainder of the HCl, the formulation was dark brown with a
AP . ύ ύ 7 Ο 6
-20small amount of suspended material. The liquefied phenol was added, the SFS was added, and a sufficient quantity of water was added to produce 4000 mL of a solution with a pH of 7.5.
The solution contained 180 mg/mL of danofloxacin based on a potency of 759 5 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 20
a/206 mL | |
danofloxacin mesylate | 59.53 |
N-methylpyrrolidone | 70.19 |
propylene glycol | 30.06 |
MgO | 9.97 |
HCl | 4.13 |
water | qs to 206 mL |
A portion of the water, a portion of the N-methylpyrrolidone, and the PVP were combined and agitated until the PVP dissolved. A portion of the HCl was added, and then the magnesium oxide. After addition of the danofloxacin mesylate to the resulting slurry, the formulation was stirred overnight. The clear amber/gold solution having a few suspending particles, was held for an additional 36 hours. The pH of the formulation was 8.0. The remainder of the HCl and the water were added, resulting in a pH of 7.5.
AP/P/ 9 6 / 0 0 8 98
The solution contained 175 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
EXAMPLE 21
=========================== a/200 mL | |
danofloxacin mesylate | 47.49 |
N-methylpyrrolidone | 20.01 |
AP. Ο & 70 6
propylene glycol | 30.01 |
polyvinylpyrrolidone (PVP) | 10.03 |
MgO | 4.09 |
HCI | 7.44 |
water | qs to 200 mL |
A portion of the water, the N-methylpyrrolidone, and the PVP were combined and agitated until the PVP dissolved. A portion of the HCI was added, and then the magnesium oxide. After the danofloxacin mesylate was added to the resulting slurry, the formulation was stirred overnight. A clear gold solution with a few suspended particles was formed and held for an additional 36 hours. After the propylene glycol was added, the pH of the formulation was 7.9. The remainder of the HCI and the water were added, resulting in a pH of 7.6.
The solution contained 180 mg/mL of danofloxacin based on a potency of 759 mg/g for the lot of danofloxacin mesylate used.
Claims (9)
1. An aqueous pharmaceutical solution which is suitable for injection into a host comprising danofloxacin or a pharmaceutically acceptable salt thereof in an amount sufficient for the treatment of bacterial infections, and (1} a magnesium compound, or (2) a zinc compound in admixture with a co-solvent, said compounds
10 and said co-solvent being present in amounts which are sufficient for improved toleration at the injection site.
2. A solution according to claim 1 wherein said magnesium compound is present together with a co-solvent.
3. A solution according to claim 1 or 2 wherein said co-solvent is at least
15 one of 2-pyrrolidone, propylene glycol, polyethylene glycol, and N-methyl-pyrrolidone, each optionally, together with polyvinylpyrrolidone.
4. A solution according to any one of claims 1,2 or 3 wherein said solution in addition contains an antioxidant.
5. A solution according to claim 4 wherein said antioxidant is sodium 20 formaldehyde sulfoxylate.
6. A solution according to any one of claims 1 to 5 wherein said solution in addition contains components to adjust the pH of said solution to about 5 to about 9.5.
7. A solution according to any one of claims 1 to 6 wherein the pH of said 25 solution is from about 6.5 to about 9.0.
8. A method for the treatment of bacterial infections in a host comprising injecting into said host an aqueous pharmaceutical solution comprising danofloxacin or a pharmaceutically acceptable salt thereof in an amount sufficient for the treatment of bacterial infections, and a (1) magnesium compound, or a (2} zinc compound in . 30 admixture with a co-solvent; said compounds and said co-solvent being present in amounts whichare sufficient for improved toleration at the injection site.
9. A method according to claim 8 wherein the treatment is by subcutaneous injection and the host is cattle.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US905295P | 1995-12-21 | 1995-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9600898A0 AP9600898A0 (en) | 1997-01-31 |
AP706A true AP706A (en) | 1998-12-04 |
Family
ID=21735307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1996/000898A AP706A (en) | 1995-12-21 | 1996-12-19 | Injectable quinolone formulations. |
Country Status (42)
Country | Link |
---|---|
US (1) | US5811130A (en) |
EP (1) | EP0868183B1 (en) |
JP (1) | JP3416145B2 (en) |
KR (1) | KR100402570B1 (en) |
CN (1) | CN1104899C (en) |
AP (1) | AP706A (en) |
AR (1) | AR005147A1 (en) |
AT (1) | ATE212551T1 (en) |
AU (1) | AU709474B2 (en) |
BG (1) | BG63933B1 (en) |
BR (1) | BR9612230A (en) |
CA (1) | CA2239352C (en) |
CO (1) | CO4480098A1 (en) |
CZ (1) | CZ293747B6 (en) |
DE (1) | DE69618987T2 (en) |
DK (1) | DK0868183T3 (en) |
DZ (1) | DZ2146A1 (en) |
EG (1) | EG24071A (en) |
ES (1) | ES2167609T3 (en) |
GT (1) | GT199600098A (en) |
HR (1) | HRP960607B1 (en) |
HU (1) | HU227918B1 (en) |
IL (1) | IL124454A (en) |
IS (1) | IS2010B (en) |
MA (1) | MA24035A1 (en) |
MX (1) | MX9805026A (en) |
MY (1) | MY117109A (en) |
NO (1) | NO315734B1 (en) |
NZ (2) | NZ501160A (en) |
OA (1) | OA10697A (en) |
PE (1) | PE25798A1 (en) |
PL (1) | PL186795B1 (en) |
PT (1) | PT868183E (en) |
RS (1) | RS49523B (en) |
RU (1) | RU2141827C1 (en) |
SI (1) | SI0868183T1 (en) |
SK (1) | SK284412B6 (en) |
TN (1) | TNSN96163A1 (en) |
TW (1) | TW449475B (en) |
UA (1) | UA56151C2 (en) |
WO (1) | WO1997023217A1 (en) |
ZA (1) | ZA9610780B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID21415A (en) * | 1997-12-05 | 1999-06-10 | Upjohn Co | QUINOLON MAGNESIUM ANTIBIOTIC COMPOUNDS |
US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
DE19937116A1 (en) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin saline formulation |
DE19937115A1 (en) | 1999-08-06 | 2001-02-08 | Bayer Ag | Aqueous drug formulation of moxifloxacin or salts thereof |
AU2001228454A1 (en) * | 2000-01-13 | 2001-07-24 | Merck Patent G.M.B.H | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
EP1356809A4 (en) * | 2000-12-28 | 2008-05-14 | Takeda Pharmaceutical | Sustained release preparations |
JP2005535644A (en) * | 2002-06-26 | 2005-11-24 | ファルマシア コーポレイション | Stable parenteral parecoxib liquid formulation |
ZA200700844B (en) * | 2004-07-02 | 2009-07-29 | Daiichi Seiyaku Co | Quinolone-containing medicinal composition |
US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
PT1901749T (en) * | 2005-05-18 | 2016-11-04 | Raptor Pharmaceuticals Inc | Aerosolized fluoroquinolones and uses thereof |
FR2896416B1 (en) | 2006-01-24 | 2010-08-13 | Vetoquinol | ANTI-INFECTIOUS COMPOSITION COMPRISING A PYRIDO (3,2,1-IJ) -BENZOXADIAZINE COMPOUND |
LT1991201T (en) * | 2006-02-10 | 2018-07-25 | Pari Pharma Gmbh | Nebulised antibiotics for inhalation therapy |
US20070197548A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone compositions |
DE102006010642A1 (en) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Drug formulations containing fluoroquinolones |
DE102006010643A1 (en) | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Using quaternary ammonium compounds to inhibit precipitation of fluoroquinolone antibiotics, particularly in ready-for-use formulations for veterinary medicine |
MX2007009796A (en) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
PL2344129T3 (en) | 2008-10-07 | 2018-07-31 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
JP2012505222A (en) | 2008-10-07 | 2012-03-01 | エムペックス・ファーマシューティカルズ・インコーポレーテッド | Inhalation of levofloxacin to reduce lung inflammation |
ES2739979T3 (en) | 2009-09-04 | 2020-02-05 | Horizon Orphan Llc | Use of levofloxacin spray for the treatment of cystic fibrosis |
MX2011007675A (en) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans. |
MX346763B (en) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne. |
MX356551B (en) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne. |
US10406149B2 (en) | 2015-06-02 | 2019-09-10 | Kyorin Pharmaceutical Co., Ltd. | Aqueous liquid formulation |
US10617684B2 (en) | 2015-06-02 | 2020-04-14 | Kyorin Pharmaceutical Co., Ltd. | Aqueous drug |
EP3305295A4 (en) | 2015-06-02 | 2019-02-20 | Kyorin Pharmaceutical Co., Ltd. | Aqueous drug |
RU2019128568A (en) * | 2017-02-13 | 2021-03-15 | Байер Энимэл Хельс ГмбХ | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN |
MX366086B (en) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0337231A2 (en) * | 1988-04-15 | 1989-10-18 | Bayer Ag | I. M. injection forms of gyrase-inhibitors |
US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
EP0470667A1 (en) * | 1990-08-10 | 1992-02-12 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Composition containing a 4-quinolone derivative complexed with a divalent metal ion |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3517709A1 (en) * | 1985-01-05 | 1986-07-10 | Bayer Ag | BASIC PREPARATIONS OF CHINOLON CARBON ACIDS |
JPS63188626A (en) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | Solubilizing pyridonecarboxylic acid |
AU647772B2 (en) * | 1989-12-29 | 1994-03-31 | Abbott Laboratories | Quinolone carboxylic acid--metal ion--acid complexes |
ATE108649T1 (en) * | 1990-02-14 | 1994-08-15 | Takeda Chemical Industries Ltd | SHOWER MIX, ITS PRODUCTION AND USE. |
US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
JPH0782141A (en) * | 1993-09-17 | 1995-03-28 | Tanabe Seiyaku Co Ltd | Injection for animal |
-
1996
- 1996-11-13 CN CN96199249A patent/CN1104899C/en not_active Expired - Lifetime
- 1996-11-13 KR KR10-1998-0704719A patent/KR100402570B1/en not_active IP Right Cessation
- 1996-11-13 AU AU73289/96A patent/AU709474B2/en not_active Expired
- 1996-11-13 JP JP52344797A patent/JP3416145B2/en not_active Expired - Lifetime
- 1996-11-13 SI SI9630422T patent/SI0868183T1/en unknown
- 1996-11-13 NZ NZ501160A patent/NZ501160A/en not_active IP Right Cessation
- 1996-11-13 HU HU9903726A patent/HU227918B1/en unknown
- 1996-11-13 NZ NZ320545A patent/NZ320545A/en not_active IP Right Cessation
- 1996-11-13 DK DK96935251T patent/DK0868183T3/en active
- 1996-11-13 IL IL12445496A patent/IL124454A/en not_active IP Right Cessation
- 1996-11-13 ES ES96935251T patent/ES2167609T3/en not_active Expired - Lifetime
- 1996-11-13 CA CA002239352A patent/CA2239352C/en not_active Expired - Lifetime
- 1996-11-13 WO PCT/IB1996/001217 patent/WO1997023217A1/en active IP Right Grant
- 1996-11-13 RU RU98111831A patent/RU2141827C1/en active
- 1996-11-13 EP EP96935251A patent/EP0868183B1/en not_active Expired - Lifetime
- 1996-11-13 CZ CZ19981930A patent/CZ293747B6/en not_active IP Right Cessation
- 1996-11-13 BR BR9612230A patent/BR9612230A/en active IP Right Grant
- 1996-11-13 UA UA98063226A patent/UA56151C2/en unknown
- 1996-11-13 SK SK807-98A patent/SK284412B6/en not_active IP Right Cessation
- 1996-11-13 PL PL96328001A patent/PL186795B1/en unknown
- 1996-11-13 PT PT96935251T patent/PT868183E/en unknown
- 1996-11-13 AT AT96935251T patent/ATE212551T1/en active
- 1996-11-13 DE DE69618987T patent/DE69618987T2/en not_active Expired - Lifetime
- 1996-11-15 TW TW085114021A patent/TW449475B/en not_active IP Right Cessation
- 1996-12-10 PE PE1996000892A patent/PE25798A1/en not_active Application Discontinuation
- 1996-12-17 EG EG113496A patent/EG24071A/en active
- 1996-12-18 MA MA24427A patent/MA24035A1/en unknown
- 1996-12-18 DZ DZ960191A patent/DZ2146A1/en active
- 1996-12-18 TN TNTNSN96163A patent/TNSN96163A1/en unknown
- 1996-12-19 AR ARP960105774A patent/AR005147A1/en active IP Right Grant
- 1996-12-19 AP APAP/P/1996/000898A patent/AP706A/en active
- 1996-12-19 HR HR960607A patent/HRP960607B1/en not_active IP Right Cessation
- 1996-12-19 US US08/769,809 patent/US5811130A/en not_active Expired - Lifetime
- 1996-12-19 GT GT199600098A patent/GT199600098A/en unknown
- 1996-12-20 RS YU69096A patent/RS49523B/en unknown
- 1996-12-20 MY MYPI96005411A patent/MY117109A/en unknown
- 1996-12-20 CO CO96066993A patent/CO4480098A1/en unknown
- 1996-12-20 ZA ZA9610780A patent/ZA9610780B/en unknown
-
1998
- 1998-05-25 IS IS4755A patent/IS2010B/en unknown
- 1998-06-12 OA OA9800082A patent/OA10697A/en unknown
- 1998-06-15 BG BG102542A patent/BG63933B1/en unknown
- 1998-06-19 MX MX9805026A patent/MX9805026A/en unknown
- 1998-06-19 NO NO19982842A patent/NO315734B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0337231A2 (en) * | 1988-04-15 | 1989-10-18 | Bayer Ag | I. M. injection forms of gyrase-inhibitors |
US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
EP0470667A1 (en) * | 1990-08-10 | 1992-02-12 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Composition containing a 4-quinolone derivative complexed with a divalent metal ion |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP706A (en) | Injectable quinolone formulations. | |
US3062717A (en) | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation | |
CS199527B2 (en) | Manufacturing process of the steady antibiotic agent | |
CA1290690C (en) | Method of reducing the swelling or pain associated with antibiotics compositions | |
AU594266B2 (en) | Nicorandil-containing preparation for injection | |
EP0769951B1 (en) | Long-acting oxytetracycline composition | |
EP1352654B1 (en) | Famotidine injections | |
EP0925065B1 (en) | Water miscible erythromycin compositions | |
WO1996001634B1 (en) | Long-acting oxytetracycline composition | |
US6110905A (en) | Long-acting oxytetracycline composition | |
US4973591A (en) | Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine | |
US20030153581A1 (en) | Stabilized difloxacin injectable solution | |
US5063220A (en) | Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine | |
CA1217425A (en) | Oxytetracyclin-solutions | |
EP0640074B1 (en) | Salts of a quinolone-carboxylic acid | |
CA2194576C (en) | Long-acting oxytetracycline composition | |
WO2000072848A1 (en) | Composition comprising (±)-5-ethyldihydro-5-(1-methylbutyl)-2-thioxo 4,6(1h,5h)-pyrimidinedione dissolved in 2,5-di-o-methyl-1,4:3,6-dianhydro-d-glucitol |